Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
chPcMab-6
- Development stage
- Preclinical
- Lead developer
- Zenoaq Resource
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
chPcMab-6 is a human-mouse chimeric monoclonal antibody targeting a cancer-specific epitope of podocalyxin (PODXL). Developed using the Cancer-Specific Monoclonal Antibody (CasMab) technology at Tohoku University, it is designed to selectively bind to podocalyxin expressed on tumor cells while sparing normal tissues, such as vascular endothelial cells, where the protein is also present. The antibody demonstrates antitumor activity through antibody-dependent cellular cytotoxicity (ADCC) and has shown efficacy in preclinical xenograft models of glioblastoma, colorectal cancer, and other solid tumors. Safety studies in cynomolgus monkeys have indicated a favorable toxicity profile, supporting its potential for clinical development in various podocalyxin-expressing malignancies.
- Other names
- anti-podocalyxin cancer-specific monoclonal antibody
02
Targets
PODXL (Podocalyxin)
Beyond the preview
Go deeper on chPcMab-6.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on chPcMab-6.